RAS-Targeted Strategies in Pancreatic Cancer

Progress and Future Directions CME/CNE/CPE

Marriott Marquis San Francisco
Friday, January 9, 2026 | 6:30 PM - 8:00 PM TZ
event presence logo
Supported by an independent educational grant from Revolution Medicines.

overview

This January in San Francisco, join a panel of 3 leading experts for a 90-minute program on the evolving landscape of pancreatic ductal adenocarcinoma (PDAC) treatment. This dynamic discussion will focus on the remarkable evolution of RAS inhibitors in PDAC, tracing the journey from when RAS was considered undruggable to the latest data on novel mechanisms and therapies targeting RAS in its active state. Don't miss this opportunity to gain insights into the future of PDAC management and engage with the experts directly during a dedicated Q&A session. 

Not an official event of the 2026 ASCO® Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Enhance Your Experience With MedChallenge!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

faculty

AGENDA

6:00 PM TZ

6:30 PM TZ

6:40 PM TZ

7:00 PM TZ

7:25 PM TZ

7:50 PM TZ

8:00 PM TZ

backstage pass
Enhance Your Virtual Experience With Backstage Pass! Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.
*Video encouraged*

LOCATION

Marriott Marquis San Francisco

780 Mission Street, San Francisco, California, 94103

Room: Yerba Buena Ballroom Salons 10-15 (Lower B2 Level)

TARGET AUDIENCE

This educational activity is intended for an audience of oncologists, gastroenterologists, pathologists, nurses, nurse practitioners/physician assistants, and pharmacists.

GOAL STATEMENT

The goal of this activity is for learners to be better able to develop more informed care plans for patients with pancreatic cancer by integrating advancing evidence on targeted therapies into real-world care decisions in the community.

LEARNING OBJECTIVES

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the[/para] [list][item]Summarizing of key clinical trial data on emerging agents that target RAS in pancreatic cancer [item]Identification of eligible patient populations for RAS-targeted therapies [item]Discussion of the future directions of RAS-targeted therapeutic strategies and their anticipated impact on precision oncology [/list] [para]Demonstrate greater confidence in their ability to[/para] [list][item]Reflect upon the impact of RAS targeting [/list]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
accreditation logo
medscape logo
[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 1.50 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text] [break] [title]For Nurses[/title] [text]Awarded up to 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.[/text] [break] [title]For Pharmacists[/title] [text]Medscape designates this continuing education activity for ​1.50​ contact hour(s) (​0.150​ CEUs) (Universal Activity Number: ​JA0007105-0000-25-416-L01-P​).[/text]
© 2025 MedscapeLIVE! All Rights Reserved | Medscape Education Terms of Service | Privacy Policy